References
- Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis. 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e227S–77S
- Heit JA, Cohen AT, Anderson FA Jr, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005;106:Abstract 910
- Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S–400S
- Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE Disease: antithrombotic therapy and prevention of thrombosis. 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S–94S
- Knight KK, Wong J, Hauch O, et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005;8:191–200
- Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441–5
- The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657–62
- Panis LJGG, Kolbach DN, Hamulyak K, et al. Identifying inappropriate hospital stay in patients with venous thromboembolism. Eur J Intern Med 2004;15:39–44
- Caprini JA, Tapson VF, Hyers TM, et al, for the NABOR Steering Committee. Treatment of venous thromboembolism. Adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005;42:726–33
- Stein PD, Hull RD, Matta F, et al. Early discharge of patients with venous thromboembolism: Implications regarding therapy. Clin Appl Thromb Hemost 2010;16:141–5
- Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444–53
- Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013 Sep 20;11(1):21
- van Bellen B, Bamber L, Correa de Carvalho F, et al. Reduction in the length of stay with rivaroxaban as a single-drug for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829–37
- Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510
- Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97
- Agency for Healthcare Research and Quality. VTE: Preventing hospital-acquired venous thromboembolism. Rockville, Maryland: AHRQ. www.ahrq.gov/qual/vtguide/vtguideapa.htm. Accessed December 11, 2013
- Spyroupoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475–86
- Knight KK, Wong J, Hauch O, et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005;8:191–200
- Huse DM, Cummins G, Taylor DC, et al. Outpatient treatment of venous thromboembolism with low-molecular- weight heparin: an economic evaluation. Am J Manag Care 2002;8:S10–S16
- Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653–61
- O’Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002;20:603–15
- Rymes NL, Lester W, Connor C, et al. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haem 2002;24:165–70
- Lin J, Lingohr-Smith M, Kwong WJ. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective. J Manag Care Pharm 2014;20:174–86
- Aujesky D, Stone RA, Kim S, et al. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: a statewide perspective. Arch Intern Med 2008;168:706–12